{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:47:50Z","timestamp":1787942870757,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharmacosmos A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02591-1","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:01:25Z","timestamp":1694563285000},"page":"4877-4888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Seiji","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-7507","authenticated-orcid":false,"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"2591_CR1","first-page":"1566","volume":"71","author":"M Okada","year":"1982","unstructured":"Okada M, Imamura K, Fuchigami T, et al. Osteomalacia caused by intravenous administration saccharated ferric oxide for treatment of iron deficiency anemia associated with nonspecific multiple ulcers of the small intestine: report of two cases. Jpn J Intern Med. 1982;71:1566\u201372.","journal-title":"Jpn J Intern Med"},{"key":"2591_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01496662","volume":"61","author":"M Okada","year":"1983","unstructured":"Okada M, Imamura K, Iida M, Omae T. Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenshr. 1983;61:99\u2013102.","journal-title":"Klin Wochenshr"},{"issue":"6","key":"2591_CR3","first-page":"316","volume":"75","author":"K Imamura","year":"1984","unstructured":"Imamura K. Effects of intravenous administration of iron preparations on the metabolism of phosphorus. Comparative study on 3 iron preparations. Fukuoka Igaku Zasshi. 1984;75(6):316\u201326.","journal-title":"Fukuoka Igaku Zasshi"},{"issue":"Pt 2","key":"2591_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46(Pt 2):167\u20139.","journal-title":"Ann Clin Biochem"},{"issue":"4","key":"2591_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1507\/endocrj.45.431","volume":"45","author":"K Sato","year":"1998","unstructured":"Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J. 1998;45(4):431\u20139.","journal-title":"Endocr J"},{"issue":"4","key":"2591_CR6","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45(4):814\u20136.","journal-title":"Bone"},{"issue":"3","key":"2591_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429\u201335.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2591_CR8","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94(7):2332\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2591_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432\u201343.","journal-title":"JAMA"},{"key":"2591_CR10","unstructured":"EU Clinical Trials Register. Clinical Trial Results: a randomized, double-blinded, comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia due to inflammatory bowel disease. EudraCT number 2017-002452-87. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-002452-87\/results. Accessed 21 Aug 2023."},{"key":"2591_CR11","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793\u2013803.","journal-title":"J Bone Miner Res"},{"key":"2591_CR12","unstructured":"Vifor Pharma UK Limited. Ferinject (ferric carboxymaltose) Ireland Summary of Product Characteristics. 2023. Irish Pharmaceutical Healthcare Association, Dublin, Ireland. https:\/\/backend-prod.medicines.ie\/uploads\/files\/648749902c1d4.pdf. Accessed 21 Aug 2023."},{"key":"2591_CR13","unstructured":"Vifor Pharma UK Limited. Ferinject (ferric carboxymaltose) UK Summary of Product Characteristics. 2023. Datapharm Ltd, Leatherhead, UK. https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc. Accessed 21 Aug 2023."},{"key":"2591_CR14","unstructured":"Takeda Pharma Ltda. Ferinject\u00ae (carboximaltose f\u00e9rrica) bula para profissional da sa\u00fade. 2021. Consulta Rem\u00e9dios, Curitiba, Brazil. https:\/\/uploads.consultaremedios.com.br\/drug_leaflet\/pro\/Bula-Ferinject-Profissional-Consulta-Remedios.pdf. Accessed 21 Aug 2023."},{"key":"2591_CR15","unstructured":"Vifor (International) Inc. Ferinject\u00ae (Eisencarboxymaltose) Fachinformationen. 2023. Refdata Foundation, Zug, Switzerland. https:\/\/www.swissmedicinfo.ch\/. Accessed 21 Aug 2023."},{"key":"2591_CR16","unstructured":"Vifor Pharma Pty Ltd. Ferinject (ferric carboxymaltose) Australian Product Information. 2023. Therapeutic Goods Administration, Woden, Australia. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2011-PI-02557-3. Accessed 21 Aug 2023."},{"key":"2591_CR17","unstructured":"American Regent, Inc. INJECTAFER\u00ae (ferric carboxymaltose injection) US prescribing information. 2020. U.S. Food and Drug Administration, Silver Spring, MD, USA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203565s009lbl.pdf. Accessed 21 Aug 2023."},{"key":"2591_CR18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s12185-022-03420-x","volume":"116","author":"H Kawabata","year":"2022","unstructured":"Kawabata H, Tamura T, Tamai S, Fujibayashi A, Sugimura M, Study Group. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. Int J Hematol. 2022;116:846\u201355.","journal-title":"Int J Hematol"},{"issue":"1","key":"2591_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12185-018-2501-8","volume":"109","author":"K Ikuta","year":"2019","unstructured":"Ikuta K, Hanashi H, Hirai K, et al. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019;109(1):41\u20139.","journal-title":"Int J Hematol"},{"key":"2591_CR20","first-page":"123","volume":"37","author":"T Uchida","year":"1996","unstructured":"Uchida T, Kawachi Y, Watanabe A, Nishihara T, Miyake T. Reevaluation of administration dosage in parenteral iron therapy. Rinsho Ketsueki. 1996;37:123\u20138.","journal-title":"Rinsho Ketsueki"},{"issue":"3\u20134","key":"2591_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","volume":"52","author":"SS Shapiro","year":"1965","unstructured":"Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika. 1965;52(3\u20134):591\u2013611.","journal-title":"Biometrika"},{"issue":"6","key":"2591_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2591_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","volume":"16","author":"D Edmonston","year":"2020","unstructured":"Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020;16(1):7\u201319.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"2591_CR24","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1681\/ASN.2016121350","volume":"28","author":"MF Eisenga","year":"2017","unstructured":"Eisenga MF, van Londen M, Leaf DE, et al. C-terminal fibroblast growth factor 23, iron deficiency, and mortality in renal transplant recipients. J Am Soc Nephrol. 2017;28(12):3639\u201346.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2591_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23(4):411\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"2591_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40264-022-01216-w","volume":"45","author":"JMM Boots","year":"2022","unstructured":"Boots JMM, Quax RAM. High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: a benefit-risk assessment. Drug Saf. 2022;45(10):1019\u201336.","journal-title":"Drug Saf"},{"key":"2591_CR27","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-11-3","author":"X Kassianides","year":"2021","unstructured":"Kassianides X, Bhandari S. Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. Drugs Context. 2021. https:\/\/doi.org\/10.7573\/dic.2020-11-3","journal-title":"Drugs Context"},{"key":"2591_CR28","unstructured":"National Institute for Health and Care Excellence. Clinical Knowledge Summary: Anaemia\u2014iron deficiency. https:\/\/cks.nice.org.uk\/topics\/anaemia-iron-deficiency\/. Accessed 19 Oct 2022."},{"issue":"6","key":"2591_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jbmr.4558","volume":"37","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports. J Bone Miner Res. 2022;37(6):1188\u201399.","journal-title":"J Bone Miner Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02591-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02591-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:39:16Z","timestamp":1697006356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02591-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2591"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02591-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"9 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Richard F Pollock is a director of Covalence Research Ltd, which received consultancy fees from Pharmacosmos A\/S to conduct the study and write the manuscript. Seiji Fukumoto received a fee from Pharmacosmos A\/S for clinical consultancy work in 2021. Tatsunori Murata and Yutaka Osuga have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All data used in the analyses were obtained from previously-conducted studies and the analyses are not reliant on data from studies of human or animal participants conducted by any of the authors. Both the JapicCTI-194573 and Ikuta et al. 2019 RCTs, on which the present analysis is based, were approved by the institutional review boards (IRBs) at each participating site. Written informed consent for participation in the studies was obtained from all subjects and both studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}